Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Nov;119(5):829–834. doi: 10.1111/j.1476-5381.1996.tb15747.x

Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells.

I Scuntaro 1, U Kientsch 1, U N Wiesmann 1, U E Honegger 1
PMCID: PMC1915950  PMID: 8922728

Abstract

1. Cationic amphiphilic drugs (CADs) are widely used in chronic pharmacotherapies in spite of frequently observed side effects connected with lysosomal phospholipid (PL) storage. 2. It has recently been shown that alpha-tocopherol (alpha-Toc) inhibits drug- and PL accumulation in cell cultures chronically exposed to the CAD, amiodarone. 3. The mechanisms of alpha-Toc action on drug kinetics and PL storage were studied in human cultured fibroblasts exposed to single and repetitive doses of desipramine and other CADs. 4. alpha-Toc did not influence the initial, pH-dependent rapid phase of drug uptake. It inhibited, in a dose-dependent manner, the slow and the cumulative phases of drug uptake and coincidently the accumulation of cellular PLs. 5. The inhibitory effects of alpha-Toc on CAD and PL accumulations depends on the ratio between CAD and alpha-Toc concentrations in the medium. This points to competition between alpha-Toc and CADs for PL complex formation. 6. Effectiveness of alpha-Toc on drug uptake varies among different CADs. It depends on its structural integrity but is independent of stereoisomerism. The inhibitory action is restricted to the piggyback slow drug uptake and therefore related to the proportion of membrane-mediated transport to permeation into lysosomes (rapid uptake). This proportion differs among CADs. 7. alpha-Toc prevents lysosomal membrane-PL storage, accelerates disintegration of PL-stores and normalizes drug-related increased membrane fluidity. This strongly suggests that alpha-Toc restores membrane recycling, impaired by CAD exposure. 8. It remains to be tested in vivo whether alpha-Toc reduces CAD side effects without interfering with drug effectiveness.

Full text

PDF
829

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams P. C., Gibson G. J., Morley A. R., Wright A. J., Corris P. A., Reid D. S., Campbell R. W. Amiodarone pulmonary toxicity: clinical and subclinical features. Q J Med. 1986 May;59(229):449–471. [PubMed] [Google Scholar]
  2. Desai I. D. Vitamin E analysis methods for animal tissues. Methods Enzymol. 1984;105:138–147. doi: 10.1016/s0076-6879(84)05019-9. [DOI] [PubMed] [Google Scholar]
  3. Fauster R., Honegger U., Wiesmann U. Inhibition of phospholipid degradation and changes of the phospholipid-pattern by desipramine in cultured human fibroblasts. Biochem Pharmacol. 1983 Jun 1;32(11):1737–1744. doi: 10.1016/0006-2952(83)90119-3. [DOI] [PubMed] [Google Scholar]
  4. Ferrari V., Cutler D. J. Uptake of chloroquine by human erythrocytes. Biochem Pharmacol. 1990 Feb 15;39(4):753–762. doi: 10.1016/0006-2952(90)90155-e. [DOI] [PubMed] [Google Scholar]
  5. Fukuzawa K., Ikebata W., Shibata A., Kumadaki I., Sakanaka T., Urano S. Location and dynamics of alpha-tocopherol in model phospholipid membranes with different charges. Chem Phys Lipids. 1992 Nov;63(1-2):69–75. doi: 10.1016/0009-3084(92)90024-j. [DOI] [PubMed] [Google Scholar]
  6. Gonzalez-Noriega A., Grubb J. H., Talkad V., Sly W. S. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J Cell Biol. 1980 Jun;85(3):839–852. doi: 10.1083/jcb.85.3.839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hein L., Lüllmann-Rauch R., Mohr K. Human accumulation potential of xenobiotics: potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis. Xenobiotica. 1990 Nov;20(11):1259–1267. doi: 10.3109/00498259009046842. [DOI] [PubMed] [Google Scholar]
  8. Hermetter A., Rainer B., Ivessa E., Kalb E., Loidl J., Roscher A., Paltauf F. Influence of plasmalogen deficiency on membrane fluidity of human skin fibroblasts: a fluorescence anisotropy study. Biochim Biophys Acta. 1989 Jan 16;978(1):151–157. doi: 10.1016/0005-2736(89)90510-5. [DOI] [PubMed] [Google Scholar]
  9. Honegger U. E., Roscher A. A., Wiesmann U. N. Evidence for lysosomotropic action of desipramine in cultured human fibroblasts. J Pharmacol Exp Ther. 1983 May;225(2):436–441. [PubMed] [Google Scholar]
  10. Honegger U. E., Scuntaro I., Wiesmann U. N. Vitamin E reduces accumulation of amiodarone and desethylamiodarone and inhibits phospholipidosis in cultured human cells. Biochem Pharmacol. 1995 Jun 16;49(12):1741–1745. doi: 10.1016/0006-2952(95)00100-e. [DOI] [PubMed] [Google Scholar]
  11. Honegger U. E., Zuehlke R. D., Scuntaro I., Schaefer M. H., Toplak H., Wiesmann U. N. Cellular accumulation of amiodarone and desethylamiodarone in cultured human cells. Consequences of drug accumulation on cellular lipid metabolism and plasma membrane properties of chronically exposed cells. Biochem Pharmacol. 1993 Jan 26;45(2):349–356. doi: 10.1016/0006-2952(93)90070-d. [DOI] [PubMed] [Google Scholar]
  12. Hostetler K. Y., Giordano J. R., Jellison E. J. In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone. Biochim Biophys Acta. 1988 Apr 15;959(3):316–321. doi: 10.1016/0005-2760(88)90205-6. [DOI] [PubMed] [Google Scholar]
  13. Joshi U. M., Rao P., Kodavanti S., Lockard V. G., Mehendale H. M. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochim Biophys Acta. 1989 Aug 22;1004(3):309–320. doi: 10.1016/0005-2760(89)90078-7. [DOI] [PubMed] [Google Scholar]
  14. Kodavanti U. P., Mehendale H. M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev. 1990 Dec;42(4):327–354. [PubMed] [Google Scholar]
  15. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  16. Lüllmann H., Lüllmann-Rauch R., Wassermann O. Lipidosis induced by amphiphilic cationic drugs. Biochem Pharmacol. 1978;27(8):1103–1108. doi: 10.1016/0006-2952(78)90435-5. [DOI] [PubMed] [Google Scholar]
  17. Lüllmann H., Wehling M. The binding of drugs to different polar lipids in vitro. Biochem Pharmacol. 1979 Dec 1;28(23):3409–3415. doi: 10.1016/0006-2952(79)90080-7. [DOI] [PubMed] [Google Scholar]
  18. Ohkuma S., Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3327–3331. doi: 10.1073/pnas.75.7.3327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Reasor M. J. Influence of a pre-existing phospholipidosis on the accumulation of amiodarone and desethylamiodarone in rat alveolar macrophages. Res Commun Chem Pathol Pharmacol. 1991 May;72(2):169–181. [PubMed] [Google Scholar]
  20. Stoffel P., Burkart T., Honegger U. E., Wiesmann U. N. Subcellular distribution of the antidepressant drug desipramine in cultured human fibroblasts after chronic administration. Drug-effect on the subcellular distribution of accumulated phospholipids. Biochem Pharmacol. 1987 Mar 1;36(5):655–662. doi: 10.1016/0006-2952(87)90716-7. [DOI] [PubMed] [Google Scholar]
  21. Toplak H., Batchiulis V., Hermetter A., Hunziker T., Honegger U. E., Wiesmann U. N. Effects of culture and incubation conditions on membrane fluidity in monolayers of cultured cells measured as fluorescence anisotropy using trimethylammoniumdiphenylhexatriene (TMA-DPH). Biochim Biophys Acta. 1990 Sep 21;1028(1):67–72. doi: 10.1016/0005-2736(90)90266-q. [DOI] [PubMed] [Google Scholar]
  22. Van Veldhoven P. P., Mannaerts G. P. Inorganic and organic phosphate measurements in the nanomolar range. Anal Biochem. 1987 Feb 15;161(1):45–48. doi: 10.1016/0003-2697(87)90649-x. [DOI] [PubMed] [Google Scholar]
  23. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974 Sep 15;23(18):2495–2531. doi: 10.1016/0006-2952(74)90174-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES